SAB Biotherapeutics (SABS) Assets Average (2021 - 2026)

SAB Biotherapeutics (SABS) has 6 years of Assets Average data on file, last reported at $210.6 million in Q1 2026.

• Quarterly Assets Average rose 411.79% year-over-year to $210.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $210.6 million (up 411.79% YoY) and the FY2025 annual result came in at $108.5 million, up 69.35% from the prior year.
• Assets Average advanced to $210.6 million in Q1 2026, from $178.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $210.6 million in Q1 2026 to a low of $31.9 million in Q3 2023.
• A 5-year average of $73.1 million and a median of $56.1 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average sank 52.18% — and 2026, when it jumped 411.79%.
• Tracing SABS's Assets Average over 5 years: stood at $51.7 million in 2022, then increased by 8.57% to $56.1 million in 2023, then decreased by 12.72% to $49.0 million in 2024, then surged by 263.56% to $178.1 million in 2025, then rose by 18.25% to $210.6 million in 2026.
• The last three Assets Average figures came in at $210.6 million (Q1 2026), $178.1 million (Q4 2025), and $106.8 million (Q3 2025), per Business Quant data.